#TrialUpdate
LightNews LightNews
vjhemonc.bsky.social
At #ASH24, we caught up with Rakesh Popat to hear the interim results of the ProMMise trial evaluating belantamab + cyclophosphamide & dexamethasone in R/R #Myeloma.

Watch here:
👉https://buff.ly/3W3Cgy2

#MMSM #CTSM #TrialUpdate #MultipleMyeloma #HemeSky #HemeOnc
@ash-hematology.bsky.social
January 5, 2025 at 12:00 PM
vjhemonc.bsky.social
Hear updates from the BP41072 trial investigating glofitamab plus englumafusp alfa in R/R B-NHL from Martin Hutchings.🩸

Click here:
👉https://buff.ly/4fGhMSJ

#LYMsm #ASH24 #NonHodgkinLymphoma #ImmunoOnc #TrialUpdate #CTSM @ash-hematology.bsky.social #Hematology #BloodSky #HemeSky #HemeOnc
January 4, 2025 at 10:00 AM
vjneurology.bsky.social
Want to hear the results of a randomized placebo-controlled Phase IIa trial investigating rozanolixizumab, an FcRn inhibitor, in patients with CIDP?

Then check out our interview with Luis Querol Gutierrez here:

🎥 https://buff.ly/4fJyPEs

#CTSM #TrialUpdate #EAN2024 #Neuroscience
December 4, 2024 at 9:00 AM
vjhemonc.bsky.social
🚨 Multiple myeloma highlights from #ASCO25!

Click below to watch Claudio Cerchione share promising developments in the field of #MultipleMyeloma from the event:

🎥 buff.ly/iiVwTX8

#Myeloma #MMSM #HemOnc #ImmunoOnc #CTSM #TrialUpdate #MedSky #BloodSky @ascocancer.bsky.social‬
June 7, 2025 at 12:01 PM
vjhemonc.bsky.social
We recently caught up with the lovely Claire Harrison of @gstt-nhs.bsky.social to hear about the promising results of the Phase II RESTORE study, evaluating elritercept in patients with #Myelofibrosis.

Watch here:
👉 https://buff.ly/4gw8OYJ

#ASH24 #MPNsm #CTSM #TrialUpdate #BloodSky #Hemesky
February 10, 2025 at 10:00 AM
vjhemonc.bsky.social
At #CART25 last week, Pere Barba of @vhio.bsky.social shared updated results from the FELIX trial, evaluating obe-cel in patients with R/R ALL.

Watch the interview here:
👉 https://buff.ly/40SDhKF 👈

#ALLsm #Leusm #CTSM #TrialUpdate #ImmunoOnc #MedSky #BloodSky #HemeSky #HemeOnc
February 13, 2025 at 5:04 PM
vjhemonc.bsky.social
Want to find out about the IMPROVE-MF trial, which is investigating a combination of imetelstat and ruxolitinib in #Myelofibrosis?

Click here to watch our interview with John Mascarenhas from #ASH24:

👉 https://buff.ly/3BEFkta 👈

#MPNs #CTSM #TrialUpdate #HemeOnc @ash-hematology.bsky.social
December 17, 2024 at 12:00 PM
vjhemonc.bsky.social
We can't wait for many exciting trial updates at #ASH24!😍

At #SOHO2024 a few months ago, Valeria Santini, MD, gave an update on the IMerge trial exploring imetelstat as a treatment for LR-MDS:

👉 https://buff.ly/48YfVaf

#MDSsm #HemOnc #CTSM #TrialUpdate
November 22, 2024 at 11:00 AM
vjhemonc.bsky.social
🎥 Dr Ian Bouligny shares the results of a Phase II trial investigating ipilimumab, nivolumab, or ipilimumab + nivolumab with/without azacitidine in R/R MDS:

👉 buff.ly/m8zEtUu 👈

#ImmunoOnc #ASH24 #MDSsm #HemOnc #CTSM #TrialUpdate #BloodSky #Hemesky
March 16, 2025 at 2:00 PM
vjhemonc.bsky.social
#18ICML | Neil Berinstein of @sunnybrookhsc.bsky.social shares updates from the BRAWM trial, which is evaluating the combination of bendamustine, rituximab, & acalabrutinib in Waldenström’s macroglobulinemia:

🎥 buff.ly/svYBGt2

#LYMsm #Lymphoma #RareDisease #HemOnc #ImmunoOnc #CTSM #TrialUpdate
August 7, 2025 at 9:01 AM
vjhemonc.bsky.social
Have you had a chance to read our comprehensive feature article on moving beyond JAK inhibitor monotherapy in #myelofibrosis?🩸

Delve into the treatment options being explored and hear exclusive expert insights:

📖 👉 buff.ly/MN0SXef

#MPNsm #CTSM #TrialUpdate #HemOnc
April 24, 2025 at 3:04 PM
vjneurology.bsky.social
To find out about the 1.5-follow-up results from the EPSILON trial of opicapone in non-fluctuating #Parkinsons disease, watch our interview from #EAN2025 with Joaquim Ferreira by clicking here:

🎥 buff.ly/2H1tGN5

#Neurology #TrialUpdate #CTSM #Neuroscience #MedSky
September 18, 2025 at 3:05 PM
vjhemonc.bsky.social
What’s new in #PNH?🩸

This week's podcast episode highlights key takeaways from #IPIG2025, including challenging clinical scenarios & valuable insights from the COMMODORE trials.

🎧 Click here to listen:
👉 ow.ly/I5a550W5nvb

#Hematology #RareDisease #CTSM #TrialUpdate
June 6, 2025 at 11:34 AM
vjhemonc.bsky.social
At #ASCO25, Andrew Kuykendall of @moffittnews.bsky.social‬ shared the rationale for investigating rusfertide in pts with #PolycythemiaVera requiring regular phlebotomies, and presented an update of the VERIFY trial.

Watch now!
🎥 buff.ly/jaRl96F

#MPNsm #CTSM #TrialUpdate @ascocancer.bsky.social‬
June 5, 2025 at 4:05 PM
vjneurology.bsky.social
🎥 Lilyana Amezcua, MD, FAAN, discusses the Phase IV CHIMES trial, evaluating ocrelizumab’s efficacy in Black/African American and Hispanic/Latino individuals with relapsing #MultipleSclerosis:

👉 https://buff.ly/4fAeFMS 👈

#MS #MultScler #AANAM #CTSM #TrialUpdate #Neuroscience #Neurology
December 1, 2024 at 6:24 PM
vjhemonc.bsky.social
🎥 Watch our interview from #ASCO25 with the fantastic Naveen Pemmaraju of @mdanderson.bsky.social‬, who presents the updated results of the CADENZA study exploring the safety & efficacy of pivekimab sunirine in #BPDCN.

Click here:
👉 buff.ly/goc03Bc

#RareDisease #TrialUpdate #CTSM #BloodSky #HemOnc
June 6, 2025 at 1:03 PM
vjneurology.bsky.social
At #ESOC2025 last month, we spoke to Dileep Yavagal to hear about a Phase I study of PKL-021, a novel matrix metalloproteinase broad-spectrum inhibitor, after ischemic #stroke.

Watch here:
👉 buff.ly/vVGvpGc

@esostroke.bsky.social‬ #MedSky #TrialUpdate #CTSM
June 16, 2025 at 9:02 AM
vjhemonc.bsky.social
Thank you to Prithviraj Bose of @mdanderson.bsky.social‬ for sharing his fantastic insights at #EHA2025!😄🩸

Hear as he outlines recent advances and trial updates in MPNs:

👉 buff.ly/lAfceBo

#MPNsm #HemOnc #ImmunoOnc #CTSM #TrialUpdate #BloodSky #MedSky #HemeSky
June 24, 2025 at 11:02 AM
vjhemonc.bsky.social
🚨 Hear results from the BEXMAB study investigating the efficacy of bexmarilimab plus azacitidine in MDS!

Watch our interview from #EHA2025 with Dr Mika Kontro here:

👉 buff.ly/HPeUP6m 👈

#MDSsm #CTSM #TrialUpdate #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
June 20, 2025 at 11:02 AM
vjhemonc.bsky.social
At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.

Watch the interview here:

👉 buff.ly/UvDvXD3 👈

#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 18, 2025 at 3:02 PM
vjhemonc.bsky.social
At #EHA2025, we had the opportunity to catch up with Amir Fathi to hear the promising results of the Phase Ib/II KOMET-001 study of ziftomenib in R/R NPM1-mutant AML.

Check out the interview here:

👉 buff.ly/IlVeBKE

#AMLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
July 21, 2025 at 9:01 AM
vjhemonc.bsky.social
At #EHA2025, Matthew Ku presented initial results of a Phase Ib study investigating JNJ-90014496, a bispecific #CARTCell therapy targeting CD19 & CD20, in CAR-T naïve pts with R/R large B-cell #lymphoma:

🎥 buff.ly/fBNjeMN

#LYMsm #TrialUpdate #CTSM #HemOnc #BloodSky #HemeSky #MedSky
July 14, 2025 at 9:02 AM
vjhemonc.bsky.social
Is a combination of isatuximab-bortezomib-lenalidomide feasible in elderly patients with #Myeloma?

Hear updates from the REST study in our interview w/ Fredrik Schjesvold at #ASH24:
👉 https://buff.ly/4ggEB0y 👈

#HemeSky #HemeOnc #MMSM #TrialUpdate #CTSM #ImmunoOnc @ash-hematology.bsky.social
December 16, 2024 at 2:30 PM
vjhemonc.bsky.social
🚨 Watch our interview with the lovely Hang Quach from #ASCO25 to hear the initial results from part I of the MagnetisMM-6 trial investigating the EDR regimen in patients with newly diagnosed #myeloma.

Click here:
👉 buff.ly/GtxXzTk

#MMSM #CTSM #TrialUpdate #HemOnc @ascocancer.bsky.social‬
June 12, 2025 at 9:01 AM
vjhemonc.bsky.social
Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT?

Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025:

👉 buff.ly/GHh6dYG 👈

#LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 20, 2025 at 5:28 PM